Nuclear Medicine and Wall Street: An Evolving Relationship
Authors:
- 3 September 2019
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 60 (Supplement) , 20S-24S
Abstract
Until recently, it has been challenging to engage Wall Street and large pharmaceutical companies in radiopharmaceutical opportunities. The modest economic prospects of most diagnostic radiopharmaceuticals have not attracted keen interest from the broader business community, despite the rapid advancement of diagnostic imaging capabilities and their increasingly crucial role in the therapeutic process. Similarly, compelling science supporting select radiopharmaceutical therapies in oncology has been overshadowed by the unique challenges posed by this class of drugs and historical commercial failures that serve as sobering reminders of risk. Fortunately, a few notable successes in the targeted radioligand therapeutic space are changing this dynamic, fueling a new flow of investor capital into these technologies and inciting increased merger and acquisition activity that has yielded significant value creation for investors. If the nuclear medicine industry is able to continue to effectively manage historical challenges, then there is significant opportunity for a new and promising wave of radioligand therapies to significantly change the oncology treatment paradigm and elevate the profile of the entire nuclear medicine sector.Keywords
This publication has 13 references indexed in Scilit:
- Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel LevineJournal of Nuclear Medicine, 2017
- Guidelines for the successful generation of protein–ligand complex crystalsActa Crystallographica Section D Structural Biology, 2017
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- Challenges in carrier‐mediated intracellular delivery: moving beyond endosomal barriersWIREs Nanomedicine and Nanobiotechnology, 2015
- Production of 177Lu for Targeted Radionuclide Therapy: Available OptionsNuclear Medicine and Molecular Imaging, 2015
- Radioiodine: The Classic Theranostic AgentSeminars in Nuclear Medicine, 2012
- Clinical development of radioimmunotherapy for B-cell non-Hodgkin’s lymphomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Manipulation of ligand binding affinity by exploitation of conformational coupling.Nature Structural & Molecular Biology, 2001
- The early history of radiotherapy: 1895–1939International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1981
- A Positron-Emission Transaxial Tomograph for Nuclear Imaging (PETT)Radiology, 1975